ANI Pharma Offers to Buy Sweden's Egetis Therapeutics to Bolster Rare Disease Franchise
ANIP is trading near its 52-week low of $69.58 (3.5% above the low).
Summary
ANI Pharmaceuticals said it has made an offer to acquire Egetis Therapeutics at SEK 11.25 per Egetis share, a move aimed at widening the scope and scale of its rare disease business. The deal would build on a portfolio already anchored by Cortrophin Gel and the recently approved Everolimus oral suspension, and it lands with ANIP shares trading near their 52-week low of $69.58 against a $95.57 high. The key open questions are whether the offer is cash or stock and how ANI would fund it — the company has a $100M buyback authorized since May, so a large cash outlay would compete with that program. Egetis is a Swedish-listed company, so the offer likely requires a public tender and regulatory clearances; watch for Egetis board response and any disclosed valuation.
At the time of this announcement, ANIP was trading at $72.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $69.58 to $95.57. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.